Drugs Made In America Acquisition (DMIIR) Total Liabilities (2024 - 2025)

Drugs Made In America Acquisition (DMIIR) reported Total Liabilities of $17.8 million for Q4 2025, up 6886.68% year-over-year from $254783.0 in Q4 2024, and down 2.07% on a QoQ basis from $18.2 million in Q3 2025.

Drugs Made In America Acquisition (DMIIR) has 2 years of Total Liabilities data on file, last reported at $17.8 million in Q4 2025.

  • Quarterly Total Liabilities rose 6886.68% year-over-year to $17.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.8 million (up 6886.68% YoY) and the FY2025 annual result came in at $17.8 million, up 6886.68% from the prior year.
  • Total Liabilities slipped to $17.8 million in Q4 2025 per DMIIR's latest filing, from $18.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $18.2 million in Q3 2025 and bottomed at $254783.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Liabilities (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn - 18.40 Mn
2 Berto Acquisition 316.66 Mn 316.66 Mn - 12.59 Mn
3 Centurion Acquisition 311.94 Mn 311.94 Mn - 13.84 Mn
4 Churchill Capital Corp IX 311.36 Mn 311.36 Mn - 11.51 Mn
5 Agriculture & Natural Solutions Acquisition 301.94 Mn 301.94 Mn - 29.40 Mn
6 Siddhi Acquisition Corp (Cayman Islands) 286.76 Mn 286.76 Mn - 16.74 Mn
7 Bold Eagle Acquisition 276.06 Mn 276.06 Mn - 9.81 Mn
8 Cartesian Growth Corp III 270.68 Mn 270.68 Mn - 14.53 Mn
9 Oyster Enterprises II Acquisition 266.84 Mn 266.84 Mn - 9.00 Mn
10 Drugs Made In America Acquisition - - - 17.80 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 17.80 Mn
Sep 30, 2025 18.18 Mn
Dec 31, 2024 254,783.00